Efficacy and safety of add-on dextromethorphan on irritability in children with ADHD treated with methylphenidate: A randomized double-blind controlled trial
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2025.119546 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Pei-Yin Pan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Hauptthemen laut MEDLINE: Dextromethorphan, Methylphenidate, Attention Deficit Disorder with Hyperactivity, Irritable Mood. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Science and Technology Council, Tri-Service General Hospital, National Defense Medical Center.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
OBJECTIVE: Converging evidence suggests that childhood irritability is prospectively associated with major depressive disorder. Dextromethorphan has shown efficacious in improving depressive symptomatology in adults. This trial aimed to investigate the efficacy and safety of add-on dextromethorphan on irritability in children with attention-deficit/hyperactivity disorder (ADHD) receiving methylphenidate treatment. METHODS: This randomized, double-blind, parallel-group trial evaluated dextromethorphan/methylphenidate versus placebo/methylphenidate in patients 7-17 years old with ADHD and comorbid irritability, which defined by the score of the Affective Reactivity Index (ARI) parent-report form ≥6. Patients were randomly assigned to receive optimal dose of methylphenidate and either dextromethorphan or placebo, 30 mg once daily for the first 2 weeks and 60 mg once daily thereafter, for a total of 8 weeks. The primary outcome was the change from baseline to week 8 in the ARI score. RESULTS: A total of 19 patients were randomized (dextromethorphan, N = 8; placebo, N = 11), and Dextromethorphan was significantly superior to the placebo in reducing the ARI score at Week 2 (-5.82 points vs. -0.32 points; least-squares mean difference - 5.50; 95 % CI -8.13, -2.87), Week 4 (-6.49 points vs. -1.96 points; least-squares mean difference - 4.53; 95 % CI -7.13, -1.94), and Week 8 (-4.98 points vs. -2.21 points; least-squares mean difference - 2.77; 95 % CI -5.29, -0.24). The effects of treatment by time interaction were significant at week 2, week 4, and week 8 (p < 0.001, p < 0.001, and p = 0.015, respectively). CONCLUSIONS: Adjunctive dextromethorphan might be efficacious in the treatment of irritability in children with ADHD treated with methylphenidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
- Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Electronic address: chinbinyeh@gmail.com.
Förderung
- National Science and Technology Council
- Tri-Service General Hospital
- National Defense Medical Center
Zitieren
APA
Pan, P. Y., & Yeh, C. B. (2025). Efficacy and safety of add-on dextromethorphan on irritability in children with ADHD treated with methylphenidate: A randomized double-blind controlled trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.119546
Vancouver
Pan PY, Yeh CB. Efficacy and safety of add-on dextromethorphan on irritability in children with ADHD treated with methylphenidate: A randomized double-blind controlled trial. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.119546
BibTeX
@article{Pan2025,
author = {Pan, Pei-Yin and Yeh, Chin-Bin},
title = {Efficacy and safety of add-on dextromethorphan on irritability in children with ADHD treated with methylphenidate: A randomized double-blind controlled trial},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2025.119546}
}
EUVIMED